Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARF6 | P62330 | 9/20 | 0.58 |
| ▸ | PLAT | P00750 | 1/20 | 0.53 |
| ▸ | PSD | A5PKW4 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19084538 | 0.95 | ARF6 (0.58) | ARF6PLATPSDKDM4EKCNQ3 | |
| SCHEMBL1286604 | 0.93 | ARF6 (0.47) | ARF6PLATKDM4EPOLBKCNQ3 | |
| SCHEMBL1279352 | 0.91 | ARF6 (0.59) | ARF6PLATPSDKDM4EKCNQ3 | |
| SCHEMBL19084547 | 0.90 | ARF6 (0.53) | ARF6PLATPSDKDM4EKCNQ3 | |
| SCHEMBL19084586 | 0.90 | ARF6 (0.53) | ARF6PLATPSDKDM4EKCNQ3 | |
| SCHEMBL19084660 | 0.89 | ARF6 (0.53) | ARF6PLATPSDKCNQ3KCNQ2 | |
| SCHEMBL19084590 | 0.89 | PSD (0.53) | ARF6PLATPSD | |
| SCHEMBL19084616 | 0.88 | PSD (0.52) | ARF6PLATPSDKCNQ3KCNQ2 | |
| SCHEMBL19084679 | 0.88 | PSD (0.52) | ARF6PLATPSDKCNQ3KCNQ2 | |
| SCHEMBL17298733 | 0.87 | ARF6 (0.63) | ARF6PLATPSDKDM4EKCNQ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8796285-B2 | Pyrazolo [1,5-a]-pyrimidones derivatives and pharmaceutical compositions and uses thereof | HEBEI MEDICAL UNIVERSITY (CN) | 2014-08-05 | — | — | US | disclosed |
| US-8796285-B2 | Pyrazolo [1,5-a]-pyrimidones derivatives and pharmaceutical compositions and uses thereof | HEBEI MEDICAL UNIVERSITY (CN) | 2014-08-05 | — | — | US | disclosed |
| US-20120088775-A1 | Pyrazolo-[1,5-a]-Pyrimidones Derivatives and Pharmaceutical Compositions and Uses Thereof | PEKING UNIVERSITY (CN) | 2012-04-12 | — | — | US | disclosed |
| US-20120088775-A1 | Pyrazolo-[1,5-a]-Pyrimidones Derivatives and Pharmaceutical Compositions and Uses Thereof | PEKING UNIVERSITY (CN) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088775-A1 | Pyrazolo-[1,5-a]-Pyrimidones Derivatives and Pharmaceutical Compositions and Uses Thereof | KCNJ2, KCNQ5, KCNJ11 | ARF6 3851/4885PLAT 1286/4885PSD 2105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.